What the July 2026 PCAC Votes Did and Did Not Do
By Karthik Achari
The July 2026 votes of the FDA's Pharmacy Compounding Advisory Committee were advisory recommendations, not final agency action. Formal notice-and-comment rulemaking must follow before any change carries legal effect.
An advisory committee exists to give the agency a record of expert opinion. Its votes are read into that record, and the agency decides what to do with them. Nothing about a vote changes what a pharmacy may compound on the day after the hearing.
That distinction matters because the gap between a recommendation and a rule is where most of the public confusion lives. Clinicians read a headline about a vote and adjust their practice as though a rule had issued. Sellers read the same headline and describe a substance as cleared. Neither reading is accurate.
The practical guidance is simple. Follow the docket rather than the coverage, read the agency's own language, and treat a recommendation as a signal about direction and not as permission.
